Table 1 Descriptive statistics for sociodemographic and clinical variables (n = 54)
Age: | Mean (SD) | 58.7 (10.8) |
Median | 61 | |
Sex: n (%) | Men | 30 (55.6%) |
Women | 24 (44.4%) | |
Time since diagnosis (weeks): | Mean (SD) | 52.5 (70.5) |
Median | 19 | |
Diagnosis: n (%) | Lung cancer | 14 (25.9%) |
Breast cancer | 11 (20.4%) | |
Lymphoma | 8 (14.8%) | |
Pancreatic or cholangiocellular cancer | 8 (14.8%) | |
Colorectal cancer | 7 (13.0%) | |
Ovarian cancer | 4 (7.4%) | |
Stomach cancer | 1 (1.9%) | |
Oesophagic cancer | 1 (1.9%) | |
Chemotherapy: n (%)* | Taxane monotherapy | 89 (15.9%) |
Gemcitabine | 59 (10.5%) | |
Capecitabine plus platin | 33 (5.9%) | |
Irinotecan and capecitabine | 33 (5.9%) | |
Ribomustin | 30 (5.3%) | |
Platin plus etoposid | 28 (5.0%) | |
Taxane plus Bevacizumab | 25 (4.5%) | |
Taxane plus platin | 25 (4.5%) | |
Irinotecan, capecitabine and bevacizumab | 22 (3.9%) | |
Pemetrexed plus platin | 19 (3.4%) | |
Vinorelbin plus platin | 19 (3.4%) | |
Irinotecan | 17 (3.0%) | |
Other | 28.9% | |
Chemotherapy line: n (%)* | Neoadjuvant | 58 (10.3%) |
Adjuvant | 91 (16.2%) | |
Curative | 26 (4.6%) | |
1. Line palliative | 183 (32.6%) | |
2. Line palliative | 111 (19.8%) | |
3. Line or more palliative | 92 (16.4%) |